SCHEMBL4603302

SCHEMBL4603302

O=[N+]([O-])c1ccnc(Cc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.49
CDK8 P49336 1/20 0.49
CYP19A1 P11511 6/20 0.48
CYP11B1 P15538 6/20 0.48
CYP11B2 P19099 6/20 0.48
RIPK1 Q13546 1/20 0.48
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CXCR3 P49682 1/20 0.45
POLB P06746 2/20 0.44
TSHR P16473 1/20 0.44
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dinitrophenylene SCHEMBL28072310 0.83 L3MBTL1 (0.54) CYP19A1CYP11B1CYP11B2RIPK1MAPT
SCHEMBL11045904 0.79 POLB (0.67) CYP19A1MEN1MAPTKMT2AALDH1A1
SCHEMBL23637665 0.78 CXCR3 (0.56) CYP19A1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL7669106 0.78 TSHR (0.43) CCNCCDK8MAPTALDH1A1POLB
SCHEMBL694426 0.76 POLB (0.43) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL2768180 0.76 TSHR (0.42) CCNCCDK8MAPTALDH1A1POLB
SCHEMBL2470383 0.76 TSHR (0.49) CCNCCDK8MAPTKMT2AALDH1A1
SCHEMBL2468958 0.76 MAPT (0.45) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL1619390 0.76 LOXL2 (0.46) CCNCCDK8MAPTALDH1A1TSHR
SCHEMBL6747115 0.75 POLB (0.57) CYP19A1CYP11B1CYP11B2RIPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1196590-B1 PROCESS OF SEPARATION OF EPOXIDE-ENANTIOMER MIXTURES BY EPOXIDE-HYDROLASE PRODUCING MICROORGANISMS BASF SE (DE) 2008-07-09 EP claimed
US-4826772-A P-NITROBENZYL PYRIDINE, AMMONIUM CHLORIDE, DEVELOPER GRAPHIC CONTROLS CANADA, LTD. (CA) 1989-05-02 US claimed
CN-117187148-A Recombinant escherichia coli producing bacillus epoxide hydrolase as well as construction method and application thereof 江西师范大学 2023-12-08 CN disclosed
US-9327033-B2 Degradation-stabilised, biocompatible collagen matrices MEDSKIN SOLUTIONS DR. SUWELACK AG (DE) 2016-05-03 US disclosed
EP-2468307-B1 Degradation-stabilised, biocompatible collagen matrices MEDSKIN SOLUTIONS DR SUWELACK AG (DE) 2015-04-22 EP disclosed
EP-2789352-A1 Degradation-stabilised, biocompatible collagen matrices MedSkin Solutions Dr. Suwelack AG (DE) 2014-10-15 EP disclosed
US-20140287006-A1 Degradation-Stabilised, Biocompatible Collagen Matrices MEDSKIN SOLUTIONS DR. SUWELACK AG (DE) 2014-09-25 US disclosed
US-8722854-B2 Degradation-stabilised, biocompatible collagen matrices MEDSKIN SOLUTIONS DR. SUWELACK AG (DE) 2014-05-13 US disclosed
US-20120165264-A1 Degradation-Stabilised, Biocompatible Collagen Matrices DR. SUWELACK SKIN & HEALTH CARE AG (DE) 2012-06-28 US disclosed
EP-2468307-A1 Degradation-stabilised, biocompatible collagen matrices Dr. Suwelack Skin & Health Care AG (DE) 2012-06-27 EP disclosed
EP-1196590-B1 PROCESS OF SEPARATION OF EPOXIDE-ENANTIOMER MIXTURES BY EPOXIDE-HYDROLASE PRODUCING MICROORGANISMS BASF SE (DE) 2008-07-09 EP disclosed
US-4419522-A ANTITUMOR AGENTS CHINOIN GYOGYSZER VEGYESZETI TERMEKEK GYARA RT. (HU) 1983-12-06 US disclosed
US-4383834-A IN THE PRESENCE OF A WATER SOLUBLE CATIONIC POLYELECTROLYTE BASF AKTIENGESELLSCHAFT (DE) 1983-05-17 US disclosed
EP-0061173-A1 Process for dyeing paper BASF Aktiengesellschaft (DE) 1982-09-29 EP disclosed
EP-0061169-A1 Method for the elimination of anionic substances from water BASF Aktiengesellschaft (DE) 1982-09-29 EP disclosed
EP-0051467-A1 Hexitol derivatives, their preparation and pharmaceutical compositions containing them CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1982-05-12 EP disclosed
US-4198433-A HYDROGEN BROMIDE SALTS OF BIS(2-DICHLOROETHYL)HYDRAZIDES OF CYSTINE AND CYSTEINE ECNPK PO BIOLOGIA I MEDIKO-BIOLOGICHNI PROBLEMI PRI BAN (BG) 1980-04-15 US disclosed
US-4144123-A EPICHLOROHYDRIN DERIVATIVE OF POLYETHER AS CROSSLINKER BASF AKTIENGESELLSCHAFT (DE) 1979-03-13 US disclosed
US-4066494-A NITROGENOUS CONDENSATION PRODUCTS USED AS RETENTION AIDS IN PAPERMAKING BASF AKTIENGESELLSCHAFT (DT) 1978-01-03 US disclosed
US-4050895-A Optical analytical device, waveguide and method MONSANTO RESEARCH CORPORATION (US) 1977-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165264-A1 Degradation-Stabilised, Biocompatible Collagen Matrices COL14A1, COL1A1, COL2A1 CCNC 1631/4885CDK8 4006/4885CYP19A1 1026/4885
US-20140287006-A1 Degradation-Stabilised, Biocompatible Collagen Matrices COL14A1, COL1A1, COL2A1 CCNC 1631/4885CDK8 4006/4885CYP19A1 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.